Category Archives: Allogeneic

Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight on Novartis (Blast 2/6)

As the cell therapy field continues to grow and evolve, companies are developing innovative strategies to overcome the current challenges that the field is facing. Below, Celltelligence provides part 2 of its analysis on Novartis’s pipeline, manufacturing technology, CDMO potential, and collaborative strategy to remain a leader in the space. In subsequent blasts, Celltelligence will provide a similar overview for BMS and Gilead (Kite). At the end of the series, Celltelligence will present a semi-qualitative analysis comparing the innovative strategies from Novartis, BMS, and Gilead (Kite).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Are Cell Therapy Leaders Losing Their Innovative Edge? Spotlight on Novartis (Blast 1/6)

As the cell therapy field continues to grow and evolve, companies are developing innovative strategies to overcome the current challenges that the field is facing. Below, Celltelligence provides a two-part analysis on Novartis’s pipeline, manufacturing technology, CDMO potential, and collaborative strategy to remain a leader in the space. In subsequent blasts, Celltelligence will provide a similar overview for BMS and Gilead (Kite). At the end of the six-part series, Celltelligence will present a semi-qualitative analysis comparing the innovative strategies from Novartis, BMS, and Gilead (Kite).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Spotlight on Poseida’s CAR-T Strategy

Since the first US CAR-T approval in 2017, the cell therapy field has rapidly evolved with 5 additional CAR-Ts receiving FDA approval. Nevertheless, challenges surrounding TATs, cost, and patient access still remain for autologous CAR-Ts. As such, off-the-shelf assets could be the answer to the industry’s current pain points. The Celltelligence team recently discussed with Eric Ostertag, Poseida’s Executive Chairman, the changing cell therapy landscape and how Poseida’s differentiated allogeneic platform could bring these life-changing therapies to a greater number of patients. Below, the Celltelligence team provides an analysis on Poseida’s allogeneic technology and how they could challenge key allogeneic and autologous competitors.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

PBCAR0191 Reports Improved Efficacy in CAR-T Relapse Patients; Precision to Evaluate PBCAR0191 with sLD; Updated Milestones for PBCAR19B and PBCAR269A; Precision Mid-Year 2022 Event

On Wednesday, June 8, Precision BioSciences held their mid-year 2022 pipeline update event (press release / presentation), highlighting updated clinical results from PBCAR0191’s (allogeneic CD19 CAR-T) Ph1/2a study in CAR-T relapse patients. Additionally, management provided updated milestones for PBCAR19B (stealth CD19 CAR-T) and PBCAR269A (allogeneic BCMA CAR-T). Below, Celltelligence provides insights on Precision’s lymphodepleting strategy for PBCAR0191 in CAR-T relapse patients, while discussing PBCAR0191’s potential regulatory pathway.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Gracell Q1 2022 Earnings Call

On Monday, May 16, Gracell held their Q1 2022 earnings call (press release / presentation).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

TCR2 Tx, Poseida, 2seventy bio, and Cellectis Q1 2022 Earnings

A series of cell therapy-related news items were observed:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Afami-cel’s BLA Filing Remains On Track for Q4 2022; ADP-A2M4N7X19’s IND Submission Planned by YE 2022; Precision’s Clinical Updates Expected in June 2022; Adaptimmune and Precision Q1 2022 Earnings Summaries

On Monday, May 9, Adaptimmune held their Q1 2022 earnings call (press release / webcast) highlighting afami-cel’s (autologous MAGE-A4 SPEAR-T; formerly ADP-A2M4) anticipated BLA filing in Q4 2022, while discussing anticipated milestones for their MAGE-A4 franchise. On the same day, Precision BioSciences reported their Q1 2022 financial results (press release) confirming multiple planned clinical updates for June 2022. Below, Celltelligence provides insights on Adaptimmune’s vector supply strategy, while discussing at which conference Precision may present their clinical updates.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene Plans to Evaluate ALLO-501A in 2L DLBCL; No Updates for Allogene’s BCMA Programs; ALLO-316’s Initial Data Likely Delayed to 2023; CF1 to Produce ~20,000 Doses Annually; Allogene Q1 2022 Earnings Call Summary

On Wednesday, May 4, Allogene held their Q1 2022 earnings call (press release) highlighting their plans to evaluate ALLO-501A (allogeneic CD19 CAR-T) in 2 DLBCL, while noting that ALLO-316’s (allogeneic CD70 CAR-T) initial clinical data may be delayed until 2023. Of note, no major updates were provided for ALLO-501A’s pivotal study or Allogene’s BCMA programs. Below, Celltelligence provides insights on how ALLO-501A could compete with autologous CAR-Ts in the 2L setting, while discussing Allogene’s upcoming clinical updates and manufacturing capabilities.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Gilead’s Oncology Deep Dive 2022: Celltelligence Analysis – Part 1

On Thursday, April 14, Gilead / Kite held their Oncology Deep Dive event, highlighting their differentiated pipeline, with key updates to their cell therapy platforms, including several new clinical trials (Presentation). Below, Celltelligence provides insights on Gilead / Kite’s expansion of Yescarta and Tecartus (CD19 CAR-Ts) into earlier lines of therapy / additional indications.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Different Strategies for Enhancing CAR-Ts to Treat Solid Tumors; Preclinical Results from Allogene’s ALLO-316; TCR2 Tx’s Allogeneic TRuC-T Platform; AACR 2022 Analysis 4

AACR 2022 Analysis 4: Several key cell therapy-related topics were discussed to overcome the challenges associated with utilizing CAR-Ts for solid tumors. Additionally, preclinical results were presented from Allogene and TCR2 Tx. Below, Celltelligence provides insights and context for each presentation. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.